U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. February 17, 2016: Risk Communication Advisory Committee Meeting Announcement - 02/17/2016
  1. Advisory Committee Calendar

Advisory Committee Meeting | In Person

Event Title
February 17, 2016: Risk Communication Advisory Committee Meeting Announcement
February 17, 2016

Date:
February 17, 2016

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

* UPDATED INFORMATION (as of 2/16/2016): The Food and Drug Administration (FDA) is modifying the start time for the meeting of the Risk Communication Advisory Committee scheduled for February 17, 2016. The modification is due to inclement weather. The meeting start time has been changed from 9am to 8am.

DateTimeLocation
February 17, 20168:00 a.m. – 4:00 p.m.Food and Drug Administation
10903 New Hampshire Ave. Building 31
Conference Center
The Great Room (Rm. 1503)
Silver Spring, MD. 20993

Agenda

On February 16 and 17, 2016, the Committee will discuss recent developments in risk communications and related sciences, and possible approaches and applications in the context of FDA communications.

FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.  Background material is available on the RCAC meeting materials page.

Procedure

Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at "Public Meetings on the FDA White Oak Campus" on the FDA website. Please note that visitors to the White Oak Campus must enter through Building 1.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the Agency's advisory committee Web page and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

  • Written submissions may be made to the contact person on or before February 9, 2016.
  • Oral presentations from the public will be scheduled between approximately 1 p.m. to 1:30 p.m. on February 16 and 17, 2016.
  • Those individuals desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before January, 25, 2016.   Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.
  • The contact person will notify interested persons regarding their request to speak by February 2, 2016.

Interested persons can also log on to https://collaboration.fda.gov/rcac/ to hear and see the proceedings.

Contact Information

  •  Lee L. Zwanziger, Designated Federal Official
    10903 New Hampshire Avenue, Building 32, Room 3354
    Silver Spring, MD 20993
  • Phone: 301-796-9151
  • Fax: 301-847-3540
  • e-mail: RCAC@fda.hhs.gov
  • FDA Advisory Committee Information Line
    1-800-741-8138
    301-443-0572 in the Washington, DC area
    Please call the information line for up-to-date information on this meeting

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Luis G. Bravo at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Official FR Notice

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Back to Top